Subtopic Deep Dive

← Protein Kinase Regulation and GTPase Signaling

PI3K-AKT-mTOR Pathway
Research Guide

What is PI3K-AKT-mTOR Pathway?

The PI3K-AKT-mTOR pathway is a central signaling cascade that regulates cell growth, proliferation, metabolism, and survival through sequential activation of phosphatidylinositol 3-kinase (PI3K), AKT kinase, and mechanistic target of rapamycin (mTOR).

Hyperactivation of this pathway drives >50% of human cancers via oncogenic mutations in PI3K or loss of PTEN phosphatase (Vivanco and Sawyers, 2002; 5987 citations). Pathway inhibitors face challenges from feedback activation of upstream receptors (O’Reilly et al., 2006; 2531 citations). Over 10 high-citation papers (2002-2012) detail its roles in cancer and inhibitor selectivity (Liu et al., 2009; 2721 citations).

Curated Papers

Key Challenges

Why It Matters

PI3K-AKT-mTOR inhibitors like everolimus target cancers with pathway mutations, improving progression-free survival in renal cell carcinoma trials. Feedback loops upon mTOR inhibition reactivate AKT via insulin/IGF-1 receptors, limiting monotherapy efficacy (O’Reilly et al., 2006). Kinase inhibitor profiling reveals off-target effects critical for clinical translation (Bain et al., 2007). PTEN loss correlates with resistance to therapies, guiding patient stratification (Song et al., 2012).

Key Research Challenges

Feedback Activation Loops

mTOR inhibition upregulates receptor tyrosine kinases, reactivating AKT and blunting anti-tumor effects (O’Reilly et al., 2006). This requires combination therapies to block upstream signals. Clinical trials show rapid pathway rebound within hours of dosing.

Inhibitor Selectivity Issues

Many PI3K/AKT inhibitors cross-react with off-target kinases, complicating efficacy attribution (Bain et al., 2007). Profiling against 70+ kinases identifies true pathway-specific compounds. Isoform-specific PI3K inhibitors demand refined selectivity screens.

PTEN Loss Resistance

PTEN tumor suppressor inactivation hyperactivates PI3K signaling, conferring resistance to downstream inhibitors (Song et al., 2012). Synthetic lethality approaches target parallel pathways. Biomarker-driven trials stratify PTEN-deficient patients.

Essential Papers

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Igor Vivanco, Charles L. Sawyers · 2002 · Nature reviews. Cancer · 6.0K citations

MAPK signal pathways in the regulation of cell proliferation in mammalian cells

Wei Zhang, Hui-Tu Liu · 2002 · Cell Research · 2.8K citations

Targeting the phosphoinositide 3-kinase pathway in cancer

Pixu Liu, Hailing Cheng, Thomas M. Roberts et al. · 2009 · Nature Reviews Drug Discovery · 2.7K citations

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · 2006 · Cancer Research · 2.5K citations

Abstract Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR...

The selectivity of protein kinase inhibitors: a further update

Jenny Bain, Lorna Plater, Matt Elliott et al. · 2007 · Biochemical Journal · 2.5K citations

The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70–80 protein kinases. On the basis of this information, the...

PI3K/Akt signalling pathway and cancer

Juan Ángel Fresno Vara, E. Casado, Javier de Castro et al. · 2003 · Cancer Treatment Reviews · 2.4K citations

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

James A. McCubrey, Linda S. Steelman, William H. Chappell et al. · 2006 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2.3K citations

Reading Guide

Foundational Papers

Start with Vivanco and Sawyers (2002; 5987 citations) for pathway-cancer overview, then O’Reilly et al. (2006; 2531 citations) for feedback mechanisms, and Bain et al. (2007; 2489 citations) for inhibitor profiling.

Recent Advances

Liu et al. (2009; 2721 citations) on therapeutic targeting; Laplante and Sabatini (2009; 2102 citations) on mTOR regulation; Song et al. (2012; 1894 citations) on PTEN functions.

Core Methods

Phosphatidylinositol lipid assays for PI3K activity; AKT/mTOR phosphorylation by Western blot; kinase inhibitor panels (Bain et al., 2007); receptor tyrosine kinase arrays for feedback (O’Reilly et al., 2006).

How PapersFlow Helps You Research PI3K-AKT-mTOR Pathway

Discover & Search

Research Agent uses searchPapers('PI3K AKT mTOR feedback loops') to retrieve O’Reilly et al. (2006), then citationGraph reveals 2500+ downstream papers on resistance mechanisms, while findSimilarPapers expands to isoform-specific inhibitors citing Liu et al. (2009). exaSearch queries clinical trial data linked to pathway mutations.

Analyze & Verify

Analysis Agent applies readPaperContent on Vivanco and Sawyers (2002) to extract mutation frequencies, verifyResponse with CoVe cross-checks feedback claims against O’Reilly et al. (2006), and runPythonAnalysis plots kinase inhibitor IC50 data from Bain et al. (2007) using pandas for selectivity heatmaps. GRADE grading scores evidence strength for clinical translation.

Synthesize & Write

Synthesis Agent detects gaps in monotherapy feedback via contradiction flagging across O’Reilly (2006) and Liu (2009), while Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations to integrate 10+ references, and latexCompile for publication-ready reviews. exportMermaid generates signaling cascade flowcharts.

Use Cases

"Analyze IC50 profiles for PI3K inhibitors from Bain 2007 using Python"

Research Agent → searchPapers('Bain kinase inhibitors') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas heatmap of 70-kinase panel) → matplotlib IC50 visualization exported as figure.

"Write LaTeX review of PI3K-AKT-mTOR feedback with citations"

Synthesis Agent → gap detection on O’Reilly 2006 → Writing Agent → latexEditText(draft text) → latexSyncCitations(10 papers) → latexCompile(PDF) with pathway diagram.

"Find GitHub code for mTOR signaling models"

Research Agent → searchPapers('mTOR signaling model') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(SBML models from Laplante and Sabatini 2009 citations) → runPythonAnalysis validation.

Automated Workflows

Deep Research workflow scans 50+ PI3K-AKT papers via searchPapers → citationGraph → structured report on inhibitor resistance (O’Reilly 2006). DeepScan's 7-step chain verifies feedback claims: readPaperContent → CoVe → GRADE → runPythonAnalysis on dose-response. Theorizer generates hypotheses for PTEN-mTOR synthetic lethality from Song et al. (2012) and Laplante (2009).

Try Doxa for PI3K-AKT-mTOR Pathway Research

Frequently Asked Questions

What defines the PI3K-AKT-mTOR pathway?

Sequential activation from PI3K lipid kinase to AKT serine/threonine kinase to mTOR complex regulates growth and survival (Vivanco and Sawyers, 2002).

What are key methods to study pathway inhibition?

Kinase selectivity profiling against 70-80 targets (Bain et al., 2007); phosphoprotein Western blots for feedback activation (O’Reilly et al., 2006).

What are seminal papers?

Vivanco and Sawyers (2002; 5987 citations) on cancer roles; Liu et al. (2009; 2721 citations) on targeting; O’Reilly et al. (2006; 2531 citations) on feedback.